Teprotumumab

替妥尤单抗

Report date: 2026/03/24 20:00:35
First In Class

Base Information

Drug NameTeprotumumab
Drug Alias NameTeprotumumab-trbwTepezzaR-1507RG-1507RO-4858696 +[7] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionInsulin-like growth factor I receptor antagonists
TargetsInsulin-like growth factor I receptor
Therapy Area/IndicationsDiabetic macular oedemaScleroderma, DiffuseGraves Ophthalmopathy +[7] 
Global Approved IndicationsGraves Ophthalmopathy
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2020/01/21
Country/TerritoryBelgiumCanadaUnited States +[19] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesGenmab A/SF. Hoffmann-La Roche Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHorizon Therapeutics Ireland DacAmgen Europe BvAmgen Inc +[6] 
Inactive CompaniesF. Hoffmann-La Roche Ltd
Active IndicationsGraves Ophthalmopathy
Inactive IndicationsDiabetic macular oedemaScleroderma, DiffuseCarcinoma, Non-Small-Cell Lung +[6] 

Other Information

ATC CodeL01XC
Related LinksWikipediaDrugBankKEGG